The view from the bottom

Spending thousands on overpriced hotel rooms or meeting spaces might seem tangential to the business of building a new company. Obviously, it wasn’t this week.

As some executives leading biotech’s newest startups told STAT, this week’s conference gave their companies an unmissable opportunity to get some attention, take the pulse of the industry, and size up potential partners and investors.

For these companies, the conference can be the best in-person introduction to biotech society. But as one CEO told STAT’s Kate Sheridan, a lot of the work done at JPM could still be accomplished in other ways. “If I had a startup company with a few million dollars in the bank, I don’t think I’d be coming to J.P. Morgan,” he said.

Read more.